Form 4: Nuvation Bio Inc. Executive Colleen Sjogren Reports Stock Option Grant and Share Acquisition

Colleen Sjogren, Chief Commercial Officer of Nuvation Bio Inc., reports the acquisition of 3,000 shares and a grant of stock options for 500,000 shares.

Summary

• Colleen Sjogren, Chief Commercial Officer of Nuvation Bio Inc., filed a Form 4 on March 4, 2025.
• The report details changes in her beneficial ownership of Nuvation Bio Inc. securities.
• On February 28, 2025, Sjogren was granted stock options to purchase 500,000 shares of Class A Common Stock at an exercise price of $1.97.
• These options vest 25% on the one-year anniversary of the grant date and then monthly over the following 36 months, contingent upon continuous service.
• Sjogren also acquired 3,000 shares of Class A Common Stock on November 19, 2024, through the company's Employee Stock Purchase Plan.
• Following these transactions, Sjogren directly owns 28,000 shares of Class A Common Stock and options to purchase 500,000 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing detailing stock transactions. The option grant is a positive for the executive, but it's a routine part of compensation.

Positives

• The grant of stock options to the Chief Commercial Officer aligns her interests with those of the shareholders, incentivizing her to contribute to the company's success.
• Participation in the Employee Stock Purchase Plan demonstrates the executive's confidence in the company's future.

Industry Context

Form 4 filings are a routine part of regulatory compliance for publicly traded companies and their insiders. They provide transparency into the transactions of company executives and directors, allowing investors to track changes in ownership and potential alignment of interests.

Comparison to Industry Standards

• Stock option grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent.
• The vesting schedule of the options (25% after one year, then monthly over 36 months) is a typical arrangement.
• Comparing the size of the option grant to those of executives at peer companies (e.g., similar-sized biotech firms) would provide further context on its relative significance.

Stakeholder Impact

• The stock option grant could potentially dilute existing shareholders if the options are exercised.
• The transactions provide transparency to shareholders regarding executive compensation and ownership.

Key Dates